Description: The true cost of a drug and its therapeutic outcome is impacted by a myriad of factors. This session will utilize case studies in high-cost, chronic diseases to illustrate to participants what factors can be critical to evaluating the true cost of a pharmaceutical intervention. Differing from session one, session two will focus on site of care, buy-and-bill aspects, and the differences between a medical and pharmacy benefit and how these factors ultimately impact the total cost of patient care.

Description: In this session, attendees will understand the role of AI in risk management and underwriting. You will see insightful case studies highlighting AI-driven techniques for enhancing precision and efficiency in these areas. Additionally, the session will cover advanced AI applications in claim management and fraud detection, showcasing cutting-edge strategies to mitigate risks and streamline operations.

Description: When actuaries and consultants evaluate various pharmaceuticals for inclusion in an employer’s benefits offering, it can be commonplace to look at the advertised list price, or WAC (wholesale acquisition cost), between products and use that as a primary driver in the evaluation process.

Description: Our panel of experts will explore 'Blue Zone' communities, the common denominators slowing the aging process and the potential impacts these initiatives could have on disability and long-term care insurance.

Description: Presenters will explore specific actuarial use cases, showcasing custom-built demonstrations and discussing a wider range of applications.

Description: The Current Environment for Pension Risk Transfer – A Roundtable Conversation

Description: The Portfolio Management course is the first part of the two-course sequence in the Investment practice area.

Description: U.S. Historical Population Mortality Rates 2000-2023

Description: Appointed actuaries are facing a number of changes in the regulatory landscape. Some of these occurred in the past few years, such as AG51 (Asset Adequacy Testing for LTC). Some were very recently put in effect and are evolving, such as AG53 (Modeling and Documentation of Complex Assets). Some are quickly approaching, such as the potential changes to asset adequacy testing requirements for reinsurance ceded by life insurers. In addition, changes to qualification requirements are on the horizon. Hear from appointed actuaries about the challenges they’ve experienced and how they’ve worked through them. Also, learn what challenges and opportunities they see in the near future and how they are preparing for coming changes.